However, the ineffectiveness of catalytic inhibition of LSD1 has been noticed in certain cancers.307,308 Therefore, targeting LSD1-involved protein interactions with the emerging technologies of PROTACs,309 not confined to the inhibition of its demethylate activity, may be a novel anticancer therapy in cancers with LSD1 overexpression like LSCC. Here, KDM1A is linked to cancer.